New and Emerging Therapies in IBD. Sarah Streett MD, AGAF Clinical Associate Professor of Medicine Stanford University
|
|
- Norma Barrett
- 6 years ago
- Views:
Transcription
1 New and Emerging Therapies in IBD Sarah Streett MD, AGAF Clinical Associate Professor of Medicine Stanford University
2 New and Emerging Therapies in IBD I have no relevant financial disclosures.
3 IBD is a Great Medical Mystery Ulcerative colitis and Crohn s disease remain incompletely understood. They are systemic processes, with manifestations that can spill over from the GI tract to involve the skin, eyes, joints, hepatobiliary system. They typically affect people in the their youth or their prime. They are on the rise world wide, both in first and developing countries. Are they autoimmune disorders, infectious diseases, environmental?
4 Genetic Susceptibility Over 160 susceptibility loci have been identified as conferring an increased risk of IBD. These are diverse disorders. The genes whose function are Genetics known impact the GI immune system. IBD is distinct in each individual. The Crohn s/uc paradigm may become outdated.
5 Epigenetics Which genes we inherit is only part of the story. Only half of the time do both identical twins both develop Crohn s disease. Epigenetics, the study of the way in which the expression of heritable traits is modified by environmental influences or other mechanisms, without a change to the DNA sequence, has increasingly come into focus. Environmental factors such as diet, exposure to antibiotics or other chemicals can modify the potential for a gene to cause a disease.
6 GI Immune System The digestive tract is our largest immunologically active surface. Alterations in immune pathways, Immune system from genetic or acquired origin, may alter the local response. Genetics The gut immune system is highly complex, and dynamic. There is increasing evidence that the gut immune system regulates our systemic immune system.
7
8 Microbiome The gut microflora outnumber our own cells by a factor of 10 to 1, and microbial DNA outnumbers human DNA by 100 to 1. The gut microbiota can be thought of as a microbial organ, which actively participates in many processes that benefit us: Immune system Digestion and energy capture from food. Defense against intestinal pathogens. Genetics Local and systemic immune response modulation and tolerance. Microbiome Synthesis of vitamins and other substances such as butyrate and SCFA which are essential.
9 Role of the Microbiome Perturbation of the microbiome has been implicated in the development of obesity, metabolic syndrome, fatty liver, as well as in IBD. Multiple factors impact the composition of our microbiome; Parental characteristics, mode of delivery, early antibiotic exposure. Diet composition has been estimated to affect 50-60% of microbiome composition- Western diet (animal protein, refined carbs, low fiber and food additives) is associated with decreased microbial diversity, as well as altered composition of bacterial phyla (lower numbers of bacteria from the phylum Bacteroidetes, greater numbers of Firmicutes) Food additives may play a role- emulsifiers cause IBD in mouse models of colitis. Goldszmid, R Nature Immunology 13, (2012)
10 Convergence of Evidence We have a convergence of evidence in the fields of genetics/epigenetics, immunology, and a rapidly growing understanding of the microbiome. Immune system Severine Vermeer described: The current hypothesis in IBD is that the disease results from a faulty immune recognition, tolerance, and defense against the commensal microbiota and dietary antigens present in Westernized diets and in a genetically susceptible host. Genetics Microbiome Environmen t
11 Principles of Therapy: 1. IBD is chronic, and progressive. 2. Treating early has benefit. 3. Everyone s disease, and response to therapy is different. 4. Combinations of medications are often the most effective. 5. It is important to monitor the disease objectively, not rely on symptoms. 6. Risks of treatment should be weighed against the risks of untreated disease progression. 7. When you find a therapy that works, continue it. 8. Steroids for a prolonged period are deleterious and indicate that alternate therapy is needed. 9. Narcotics are contraindicated, mask symptoms and worsen outcomes.
12 Goals of Therapy 1- Relieve symptoms 2- Clinical remission 3- Steroid free remission 4- Mucosal healing 5- Histologic healing
13 Treatment Phases 1. Induction- people are often the sickest, and most motivated. This is a high risk time. 2. Maintenance- once remission has been achieved, compliance becomes a common issue. 3. Episodic treatment leads to irreversible organ damage, and flares may not respond to treatment that worked before. 4. Chronic inflammation is a risk for cancer.
14 Mainstay IBD Therapy: 5-ASA or Sulfasalazine- Can be effective for mild colitis. Beneficial to combine w topicals. Steroids remain important as induction agents, but should never be given for prolonged courses. Immunomodulators 6-MP/Imuran and Mtx have better efficacy in UC- Biologics- anti-tnf
15 Risk Assessment: Top down therapy concept- Evolved to a paradigm of patent risk assessment, and top vs. accelerated step up therapy. High risk features: Young age Severe disease Extensive disease (pan-colitis, small bowel/ugi CDz) Fistulizing, stenosing, or rectal Crohn s Need for more than one course of steroids
16 Anti-integrin Therapies: Vedolizumab Etrolizumab- Anti-integrin therapies Alicaforsen Anti IL 12/23: Usteminumab JAK-STAT Inhibitors: Tofacitinib- Other mechanisms of action: Mongersen- Antisense Smad7 Ozanimod- S1P Receptor New and Emerging Therapies
17 Anti-Integrin Therapies Family of medications that are antibodies that bind to integrin receptors. Integrins are expressed on white blood cells and allow them to dock along the blood vessel in order to migrate into different tissues. Blocking integrins can decrease inflammation by preventing white cells from entering into the intestine.
18 Vedolizumab Vedolizumab was FDA approved in 2014 for the treatment of both Crohn s and UC. Humanized (IgG1) mab against alpha-4-beta-7 integrin, that interferes only with the alpha-4-beta- 7/MAdCAM-1 interaction. Alpha-4-beta-7 is expressed selectively in the GI tract. First GI specific IBD therapy, appears in have an excellent safety profile. Colombel et al, GUT, Feb 2016
19 Vedolizumab:
20 Etrolizumab: Humanized monoclonal antibody against both alpha 4 beta7 and alpha e beta7. Alpha e beta 7 action blocks white cell retention in the epithelium through binging with e cadherin, potentially given it greater effectiveness. It is in Phase III trials now for UC and Crohn s.
21 Alicaforsen Anti-adhesion therapy which blocks an activated leukocyte receptor on endothelial cells. It is a small molecule intracellular treatment which targets mrna to decrease production of ICAM-1. We are starting a clinical trial at SUH first in people who have had colectomy with IAPP, and have chronic pouchitis.
22 Ustekinumab Approved by the FDA in 2009 for the treatment of psoriasis. Fully human IgG1 antibody that binds to interleukins 12 and 23 by the p40 subunit. IL 12 and IL 23 are proinflammatory cytokines, and induce differentiation of Th1 and Th17 t cells, which are instigators in IBD pathogenesis. Genetic changes in the genes encoding IL 23 have been found in people with IBD.
23 Ustekinumab: Uniti phase III trial showed effectiveness in moderate/severe Crohn s disease, for both induction and maintenance of short term remission. No malignancies, opportunistic infections, cases of tuberculosis or major adverse cardiovascular events were observed in patients treated with Stelara. However TB and other opportunistic infections, skin cancers, and a rare neurologic condition have occurred in the psoriasis population. Small increase in cardiovascular issues was not found to be statistically significant, but continues to be monitored. Expect this to be available for Crohn s late this year.
24 Tofacitinib: Janus kinases (Jaks) & signal transducers, and activators of transcription (Stats) are intracellular signaling molecules that mediate the signal of initial ligand-receptor binding to modulation of gene expression. FDA approved as Xeljanz for the treatment of rheumatoid arthritis Tofacitinib is a pan-jak inhibitor that preferentially binds to Jak1 and 3, diminishing the downstream effects of several IBD-associated cytokines. This is a small molecule therapy, taken orally. It works at an earlier stage in the inflammatory process.
25 Tofacitinib: Phase II data for UC was promising, and currently Phase III OCTAVE trials are underway. Initial results for the Induction in moderate to severe UC were favorable at 8 weeks, with good safety profile Crohn s Phase II data was mixed potentially due to very high placebo response, but Phase III also underway. Potential safety issues being monitored are suppressed white cell counts, cholesterol elevations, TB reactivation, and potential increase risk of intestinal perforation and malignancies.
26 Mongersen Small molecule and acts inside the cell to interfere with a suppressor of antiinflammation genes. Binding (and degrading) target mrna with antisense molecules allows specific inhibition this involved pathway. Targets early events in intestinal inflammatory to reset the mucosal immune system homeostasis. Phase II study in Crohn s disease resulted in a clinical response that was sustained over three months. Safety monitoring needed for kidney issues, increased risk of fibrosis. Vanhove et al, CLINICAL PHARMACOLOGY & THERAPEUTICS ANUARY 2016
27 Ozanimod Small molecule, taken orally Induces internalization of a receptor on memory T cell lymphocytes that facilitates their exit from lymph nodes into the circulation. Phase II study in UC showed improved mucosal healing at 8 weeks. Phase II study for Crohn s underway.
28 Emerging Therapies: IBD is unique in different people, as are responses to treatments. Significant progress is being made to develop targeted treatments to halt the disease process. The goal of therapy should be steroid free disease remission. Personalization of therapy is the future.
Medical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationResearch Update: Looking for the Answers
Research Update: Looking for the Answers Ted Denson, M.D. Schubert-Martin Inflammatory Bowel Disease Center Research Support: NIH/NIDDK, CCFA, BMRP Figure 2 Approach to Improve Outcomes for our IBD Patients
More informationPEDIATRIC INFLAMMATORY BOWEL DISEASE
PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease
More informationNew and Future Adhesion Molecule Based Therapies in IBD
New and Future Adhesion Molecule Based Therapies in IBD Brian G. Feagan Professor of Medicine, Epidemiology and Biostatistics University of Western Ontario Robarts Clinical Trials London, Ontario, Canada
More informationTherapies for IBD: the Pipeline. New Therapeutic Agents in IBD
Therapies for IBD: the Pipeline New Therapeutic Agents in IBD William J. Sandborn, MD Professor & Chief, Division of Gastroenterology Director, UCSD IBD Center Budesonide Oral MMX budesonide Rectal budesonide
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationPersonalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment
Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis
More informationGenetics. Environment. You Are Only 10% Human. Pathogenesis of IBD. Advances in the Pathogenesis of IBD: Genetics Leads to Function IBD
Advances in the Pathogenesis of IBD: Genetics Leads to Function Pathogenesis of IBD Environmental Factors Microbes Scott Plevy, MD Associate Professor of Medicine, Microbiology & Immunology UNC School
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationSelective leucocyte trafficking inhibitors for treatment of IBD
Selective leucocyte trafficking inhibitors for treatment of IBD Séverine Vermeire MD, PhD Department of Gastroenterology University Hospitals Leuven Belgium Migration of Leucocytes plays a key role in
More informationEffector T Cells and
1 Effector T Cells and Cytokines Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School 2 Lecture outline Cytokines Subsets of CD4+ T cells: definitions, functions, development New
More informationNew treatment options in IBD: today and the future. Silvio Danese Istituto Clinico Humanitas, Milan, Italy
New treatment options in IBD: today and the future Silvio Danese Istituto Clinico Humanitas, Milan, Italy Date of preparation: October 2014 GLO/EYV/2014-00010h Overview of the late-stage IBD drug pipeline*
More informationGut Microbiota and IBD. Vahedi. H M.D Associate Professor of Medicine DDRI
Gut Microbiota and IBD Vahedi. H M.D Associate Professor of Medicine DDRI 1393.3.1 2 GUT MICROBIOTA 100 Trillion Microbes - 10 times more than cells in our body Collective weight of about 1kg in human
More informationEfficacy of Vedolizumab as Induction Therapy for Inflammatory Bowell Disease in a «real-life» Study. Clinical Study
Efficacy of Vedolizumab as Induction Therapy for Inflammatory Bowell Disease in a «real-life» Study Clinical Study Q. Trefois (1), O. Descamps (2), J-C. Coche (3), M. Schapira (4) 1 Depar t m ent o f H
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationFaecalibacterium prausnitzii
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients PNAS 105(43): 16731-16736, 2008. Speaker: Ming-Cheng Chen Advisor:
More informationPathophysiologic Basis of Autoimmune Disorders
Pathophysiologic Basis of Autoimmune Disorders Linda Felver, Ph.D., R.N. Associate Professor School of Nursing Oregon Health & Science University The immune system has two arms: Adaptive (Acquired) Immune
More informationPositioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
More informationHOW THE MICROBIOME AFFECTS OUR HEALTH
HOW THE MICROBIOME AFFECTS OUR HEALTH THE INTESTINAL BARRIER AND INTESTINAL PERMEABILITY Intestinal Barrier: a functional body Defense from translocation of dietary antigens, bacteria or bacterial endotoxins
More informationThe enteric microbiota: Implications for IBD. Eugene B. Chang, M.D. University of Chicago
The enteric microbiota: Implications for IBD Eugene B. Chang, M.D. University of Chicago On a per cell basis, humans are mostly prokaryote 100 90 80 70 60 50 40 30 20 10 0 EuK ProK The microbial flora
More informationFuture Directions in IBD: Treatments & Approaches JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER APRIL 29, 2018
Future Directions in IBD: Treatments & Approaches JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER APRIL 29, 2018 Why do pharmaceuticals dominate IBD therapy discussions?
More informationMichael D. Kreines, M.D.
Michael D. Kreines, M.D. Gastroenterology Section Chief Medical Director, IBD Program The Christ Hospital of Cincinnati Ohio GI and Liver Institute www.ohiogi.com This Year s Story How to figure out how
More informationBiologic Therapy for Ulcerative Colitis in 2015
5/6/215 Biologic Therapy for Ulcerative Colitis in 215 John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Bressler B, Marshall JK, et al. Gastroenterology 215;148: 135-58
More informationClinical Trials in IBD. Bruce Yacyshyn MD Professor of Medicine Division of Digestive Diseases
Clinical Trials in IBD Bruce Yacyshyn MD Professor of Medicine Division of Digestive Diseases Objectives Today s discussion will address the following topics: Similarities and differences between Crohn
More informationUpdate in Pediatric IBD: 2018
Update in Pediatric IBD: 2018 Jeffrey S. Hyams, MD Head, Division of Digestive Diseases, Hepatology and Nutrition Mandell-Braunstein Family Endowed Chair in Pediatric Inflammatory Bowel Disease Connecticut
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationT Lymphocyte Activation and Costimulation. FOCiS. Lecture outline
1 T Lymphocyte Activation and Costimulation Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline T cell activation Costimulation, the B7:CD28 family Inhibitory receptors of T cells Targeting costimulators for
More informationMicrobiome in You: Optimizing Gut Bacteria for Better IBD Management
Microbiome in You: Optimizing Gut Bacteria for Better IBD Management KT Park, M.D., M.S. Assistant Professor Co-Director, Stanford Children s Inflammatory Bowel Disease Center Stanford University School
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationCrohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine
Crohn's disease Crohn's disease is an inflammatory condition of the digestive tract that affects children and adults. Common features of Crohn's disease include mouth sores, diarrhea, abdominal pain, weight
More informationExosomes as a. Novel Therapeutic Approach to Gastrointestinal Diseases Rebecca Murray APRN, FNP, CDE
Exosomes as a Novel Therapeutic Approach to Gastrointestinal Diseases Rebecca Murray APRN, FNP, CDE Endocrine Nurse Practitioner Institute for Hormonal Balance Orlando, FL Medical Director Ward-Murray
More informationJAK-STAT Signaling and Disease Pathogenesis in RA and IBD
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationRole of JAKs in myeloid cells and autoimmune diseases. Satoshi Kubo, Kunihiro Yamaoka and Yoshiya Tanaka
131 Mini Review Role of JAKs in myeloid cells and autoimmune diseases Satoshi Kubo, Kunihiro Yamaoka and Yoshiya Tanaka The First Department of Internal Medicine, University of Occupational and Environmental
More information4/16/2018. Go with your gut: the gutjoint. Learning objectives: Disclosure of Conflicts of Interest. Collaboration: OpenBiome
Go with your gut: the gutjoint axis James T. Rosenbaum April 27, 2018 Rheumatology Research Foundation Spondylitis Association of America Disclosure of Conflicts of Interest Collaboration: OpenBiome Funding:
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationThe Gut Microbiota: Evidence For Gut Microbes as Contributors to Weight Gain
The Gut Microbiota: Evidence For Gut Microbes as Contributors to Weight Gain Michael T. Bailey, Ph.D. Center for Microbial Pathogenesis The Research Institute, Nationwide Children s Hospital Department
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationUse of extrapolation in small clinical trials:
Use of extrapolation in small clinical trials: Infliximab for pediatric ulcerative colitis Jessica J. Lee, MD, MMSc Medical Officer Division of Gastroenterology and Inborn Errors Products CDER/ FDA 1 Learning
More information17 th International Conference of the Inflammation Research Association: Wednesday AM (Day 4) September 9-13, 2012
17 th International Conference of the Inflammation Research Association: Wednesday AM (Day 4) September 9-13, 2012 The Sagamore Resort, Bolton Landing, NY, USA The following report includes highlights
More informationAntigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
More informationSER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017
SER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017 Leading the Microbiome Revolution Forward Looking Statements Some of the statements in this presentation
More informationRegulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio
More informationDysbiosis & Inflammation
MASTERING THE MICROBIOME: Dysbiosis & Inflammation 2017 Tom Fabian, PhD It is reasonable to propose that the composition of the microbiome and its activities are involved in most, if not all, of the biological
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationWhat Have We Learned About the Microbiome in Pediatric IBD?
What Have We Learned About the Microbiome in Pediatric IBD? Ted Denson, MD Cincinnati Children s Hospital Medical Center and the University of Cincinnati College of Medicine Disclosures: NIH, CCF, AbbVie
More informationMicrobiome GI Disorders
Microbiome GI Disorders Prof. Ram Dickman Neurogastroenterology Unit Rabin Medical Center Israel 1 Key Points Our gut microbiota Were to find them? Symbiosis or Why do we need them? Dysbiosis or when things
More informationBibliografia Microbiota
Bibliografia Microbiota Systematic Review: Gut Microbiota in Fecal Samples and Detection of Colorectal Neoplasms. The role of the intestinal microbiome in ocular inflammatory disease. The gut microbiome
More informationImmunity and Infection. Chapter 17
Immunity and Infection Chapter 17 The Chain of Infection Transmitted through a chain of infection (six links) Pathogen: Disease causing microorganism Reservoir: Natural environment of the pathogen Portal
More informationOutline. Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic. Biologic Drugs. Biologic Drugs. Biologic Drugs Anti-TNF
Outline Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic Types of biologic drugs How do they work? How effective are they? Safety/Toxicity concerns with biologics Biologic
More information4/17/2019 DISCLOSURES OBJECTIVES GI MICROBIOME & HEALTH: A REVIEW. Nancy C. Kois, MD, FCAP Contemporary Pathology Services. There are no disclosures
GI MICROBIOME & HEALTH: A REVIEW Nancy C. Kois, MD, FCAP Contemporary Pathology Services DISCLOSURES There are no disclosures OBJECTIVES Definitions: GI microbiota, GI microbiome, probiotic, prebiotic
More informationClinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut
Clinically proven to quickly relieve symptoms of common gastrointestinal disorders GASTROINTESTINAL DISEASE Referred to as gastrointestinal diseases, they are common disorders which affect the esophagus,
More informationIs there an anti-inflammatory diet in IBD?
CCFA North Texas Chapter IBD education symposium December 2, 2017, Dallas, TX Is there an anti-inflammatory diet in IBD? Themos Dassopoulos, MD Director, Baylor Scott and White Center for IBD Baylor University
More informationCytokines modulate the functional activities of individual cells and tissues both under normal and pathologic conditions Interleukins,
Cytokines http://highered.mcgraw-hill.com/sites/0072507470/student_view0/chapter22/animation the_immune_response.html Cytokines modulate the functional activities of individual cells and tissues both under
More informationMicrobiome, Inflammation and Cancer
Microbiome, Inflammation and Cancer Anita Afzali MD, MPH, FACG Medical Director, OSU Inflammatory Bowel Disease Center Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease 4 th Annual Cancer
More informationImmunological Tolerance
Immunological Tolerance Definition: Making sure antibodies or T cells recognizing self components are either eliminated or brought under tight control. Failure of tolerance can lead to autoimmunity. (Also
More informationThe New and Emerging Agents: Dermatology
Psoriasis Treatment 2013: What is New and on the Horizon? Neil J Korman, MD, PhD Professor of Dermatology University Hospitals Case Medical Center Clinical Director Murdough Family Center for Psoriasis
More informationIntestinal Microbiota in Health and Disease
Intestinal Microbiota in Health and Disease February 27, 2015 Master s Course in Gastroenterology Prof. Kathy McCoy 1 Overview Overview of Gut Microbiota Microbiota in Health Microbiota in Disease 2 Gut
More informationInnate immune regulation of T-helper (Th) cell homeostasis in the intestine
Innate immune regulation of T-helper (Th) cell homeostasis in the intestine Masayuki Fukata, MD, Ph.D. Research Scientist II Division of Gastroenterology, Department of Medicine, F. Widjaja Foundation,
More informationGenetics of Pediatric Inflammatory Bowel Disease
Genetics of Pediatric Inflammatory Bowel Disease Judith Kelsen MD Assistant Professor of Pediatrics Division of Gastroenterology, Hepatology, and Nutrition IBD Education Day 2/9/2014 Objectives Brief overview
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 11 T-Cell Activation, Differentiation, and Memory Copyright 2013 by W. H. Freeman and
More informationSpeaker Introduction
Speaker Introduction Stephen B. Hanauer, MD Professor of Medicine and Clinical Pharmacology University of Chicago Pritzker School of Medicine Chief of Gastroenterology, Hepatology, and Nutrition University
More informationInflammatory Bowel Disease: Clinical updates. Dr Jeff Chao Princess Alexandra Hospital
Inflammatory Bowel Disease: Clinical updates Dr Jeff Chao Princess Alexandra Hospital Inflammatory bowel disease 2017 Clinical updates and future directions Pathogenesis Treatment targets Therapeutic agents
More informationLavanya Nutankalva,MD Consultant: Infectious Diseases
Lavanya Nutankalva,MD Consultant: Infectious Diseases Introduction The word Probiotic was derived from the Greek phrase meaning for life." was first coined in the 1960s by Lilly and Stillwell. Probiotics
More informationALLERGY AND AUTOIMMUNITY
ALLERGY AND AUTOIMMUNITY Allergies and Autoimmunity Allergies and autoimmunity can be prevented It all starts in the gut It is more than preventing leaky gut IgE allergies do not necessarily involve leaky
More informationNew IBD Therapies Promise and Pitfalls. Frederick L. Makrauer, MD Center for Crohn s and Colitis Brigham and Women s Hospital March 12, 2016
New IBD Therapies Promise and Pitfalls Frederick L. Makrauer, MD Center for Crohn s and Colitis Brigham and Women s Hospital March 12, 2016 None Conflicts of Interest and Disclosures Treatments we will
More informationInflammatory Bowel Disease A model for translational medicine. D P Jewell Professor Emeritus of Gastroenterology University of Oxford
Inflammatory Bowel Disease A model for translational medicine D P Jewell Professor Emeritus of Gastroenterology University of Oxford Samuel Wilks 1859, Pathological Treatises of Guy s Hospital The London
More informationFOR OPTIMAL GUT HEALTH KEMIN.COM/GUTHEALTH
FOR OPTIMAL GUT HEALTH KEMIN.COM/GUTHEALTH ALETA A SOURCE OF 1,3-BETA GLUCANS Aleta is highly bioavailable, offering a concentration greater than 5% of 1,3-beta glucans. Aleta provides a consistent response
More informationThe first lecture on this day was given IBD THERAPEUTIC AND BIOLOGICAL BARRIERS IBD 2017 BERLIN FALK SYMPOSIUM 209
IBD 2017 - THERAPEUTIC AND BIOLOGICAL BARRIERS Falk Symposium 209 had a program that aimed to shed light into the better understanding of the intestinal microflora and the subsequent interaction with the
More informationLatest Meds Approved for IBD: What are they and how do they work?
Latest Meds Approved for IBD: What are they and how do they work? JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER SEPT 30, 2018 Brief history of IBD Dr. Burrill Crohn JAMA
More informationFuture Therapies in IBD. William J. Sandborn, M.D. Mayo Clinic, Rochester, Minnesota
Future Therapies in IBD William J. Sandborn, M.D. Mayo Clinic, Rochester, Minnesota Korzenik et al. Nature Reviews Drug Discovery 5, 197 209 (March 2006) doi:10.1038/nrd1986 Therapies for IBD: The Pipeline
More informationGut Microbiome Essentials
CORE COMPONENTS I: Gut Microbiome Essentials 2016 Tom Fabian, PhD Module Outline 1. Microbiome overview: getting a sense of the microbiome, research, what we know 2. Bacteria: features, functions, communities
More informationChronic Granulomatous Disease Managing GI Issues
Chronic Granulomatous Disease Managing GI Issues N I C H O L A S H A R T O G, M D D i r e c t o r o f P e d i a t r i c / A d u l t P r i m a r y I m m u n o d e f i c i e n c y C l i n i c A s s i s t
More informationBeyond the Scope: The Microbiome & The Future of Gastroenterology
Beyond the Scope: The Microbiome & The Future of Gastroenterology Robynne Chutkan, MD, FASGE Digestive Center for Wellness, LLC MedStar Georgetown University Hospital Rapid Identification of Microbes
More informationBeyond the Scope: An Integrative Gastroenterologist s Approach to Digestive Disorders
Beyond the Scope: An Integrative Gastroenterologist s Approach to Digestive Disorders Robynne Chutkan, MD, FASGE Digestive Center for Wellness, LLC MedStar Georgetown University Hospital The real voyage
More informationMucosal Immunology Sophomore Dental and Optometry Microbiology Section I: Immunology. Robin Lorenz
Mucosal Immunology Sophomore Dental and Optometry Microbiology Section I: Immunology Robin Lorenz rlorenz@uab.edu Why do we Need to Understand How the Mucosal Immune System Works? The mucosa is the major
More informationInflammatory Bowel Diseases (IBD) Clinical aspects Nitsan Maharshak M.D., IBD Center, Department of Gastroenterology and Liver Diseases Tel Aviv Soura
Inflammatory Bowel Diseases (IBD) Clinical aspects Nitsan Maharshak M.D., IBD Center, Department of Gastroenterology and Liver Diseases Tel Aviv Sourasky Medical Center Tel Aviv, Israel IBD- clinical features
More informationLooking for Answers. IBD Research March 9, Dr. Benjamin Click, MD MS Associate Staff Cleveland Clinic
Looking for Answers IBD Research 2019 March 9, 2019 Dr. Benjamin Click, MD MS Associate Staff Cleveland Clinic Disclosures No relevant financial disclosures There is still no cure for IBD Why me? ETIOLOGY
More informationCD4+ T Helper T Cells, and their Cytokines in Immune Defense and Disease
CD4+ T Helper T Cells, and their Cytokines in Immune Defense and Disease Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture outline Intro to T cell mediated immunity
More informationSelby Inflamm Bowel Dis. 2008:14:
Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory
More informationEmerging Therapies in IBD: The Future is Bright October 28 th 2017
Emerging Therapies in IBD: The Future is Bright October 28 th 2017 Nirmal Kaur, MD Director, Inflammatory Bowel Disease Center Division of Gastroenterology Henry Ford Health System Disclosures Research
More informationJAK Inhibition in Inflammatory Bowel Disease
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationComplementary & Alternative Therapies in IBD
Complementary & Alternative Therapies in IBD Laurie Rosales, APRN-CNP OSU Wexner Medical Center Division of Gastroenterology, Hepatology and Nutrition Complementary & Alternative Probiotics Cannabis Fish
More informationCrohn's Disease. What causes Crohn s disease? What are the symptoms?
Crohn's Disease Crohn s disease is an ongoing disorder that causes inflammation of the digestive tract, also referred to as the gastrointestinal (GI) tract. Crohn s disease can affect any area of the GI
More informationThe National Association of Crohn s and Colitis of Trinidad and Tobago CROHN S DISEASE AND ULCERATIVE COLITIS GENERAL PATIENT INFORMATION
The National Association of Crohn s and Colitis of Trinidad and Tobago CROHN S DISEASE AND ULCERATIVE COLITIS GENERAL PATIENT INFORMATION You are reading this pamphlet because you or someone you known
More informationInflammatory bowel disease: cause(s), cure(s) and prediction of disease flare NZ Society of GI: 21 st November 2018
Inflammatory bowel disease: cause(s), cure(s) and prediction of disease flare NZ Society of GI: 21 st November 2018 Dr Charlie Lees Consultant Gastroenterologist From the Edinburgh IBD Unit at the Western
More informationIssues at Hand. Inflammatory Bowel Disease Paradigm. Diet changes the fecal microbiome. Experience with diet in IBD
Diet s Role in IBD David Suskind M.D. Professor of Pediatrics Director of Clinical Gastroenterology Division of Gastroenterology University of Washington Seattle Children s Hospital Issues at Hand Inflammatory
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationThe role of gut microbiome in IBS
The role of gut microbiome in IBS Chung Owyang, MD H. Marvin Pollard Professor of Internal Medicine Professor of Molecular and Integrative Physiology Chief, Division of Gastroenterology Director, Pollard
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi
More informationGalapagos Mechelen, Belgium, and Romainville, France. Digestive Disease Week 2014 pres# 188 Saturday, May 3
Exploration of GLPG0634, the first selective JAK1 inhibitor, in Inflammatory Bowel Disease is supported by early clinical results and mouse DSS-colitis data René Galien, Didier Merciris, Frédéric Vanhoutte,
More informationGut Lung Axis Implication of the Gut Microbiota beyond its niche
Gut Lung Axis Implication of the Gut Microbiota beyond its niche Reema Subramanian PhD Candidate (4 th year) Supervisor: Prof. Margaret Ip Department of Microbiology, CUHK Joint Graduate Student Seminar
More informationCROHN S DISEASE AND ULCERATIVE COLITIS
Slide 1 CROHN S DISEASE AND ULCERATIVE COLITIS Slide 2 Slide 3 Crohn s Inflammation in the GI tract but usually in the lower part of the small intestines and the colon. Inflammation occur between healthy
More informationTolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases. Abul K. Abbas UCSF
Tolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases Abul K. Abbas UCSF Balancing lymphocyte activation and control Activation Effector T cells Tolerance Regulatory T cells
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: Feb. 14, 2018 Last Revised: April 1, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationUNDERSTANDING CROHN S DISEASE
UNDERSTANDING CROHN S DISEASE START YOUR JOURNEY TOWARD UNDERSTANDING INFLAMMATORY BOWEL DISEASE CONTENTS INTRODUCTION 4 WHAT IS CROHN S DISEASE? 6 Symptoms of Crohn s disease 6 WHAT CAUSES CROHN S DISEASE?
More informationPBS Class #2 Introduction to the Immune System part II Suggested reading: Abbas, pgs , 27-30
PBS 803 - Class #2 Introduction to the Immune System part II Suggested reading: Abbas, pgs. 15-25, 27-30 Learning Objectives Compare and contrast the maturation of B and T lymphocytes Compare and contrast
More informationMy Child Has Inflammatory Bowel Disease : Why? What now? What s next?
My Child Has Inflammatory Bowel Disease : Why? What now? What s next? George M. Zacur, M.D., M.S. Clinical Assistant Professor Department of Pediatrics and Communicable Diseases Division of Gastroenterology
More information